Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Bibby

Showing results (181-190 of 204) with videos related to

Pageof 21
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 11, 2005
Differentiation and definition of vascular-targeted therapiesDietmar W Siemann, Michael C Bibby, Graham G Dark, et al.
British Journal of Cancer|June 28, 2002
Heterogeneity of O6-alkylguanine DNA-alkyltransferase expression in human breast tumoursM J Clemons, M C Bibby, H El Teraifi, et al.
BMJ Open|November 10, 2022
Protocol for a prospective observational cohort study collecting data on demographics, symptoms and biomarkers in people with mesothelioma (ASSESS-meso)Ruairi J H Conway, Jenny Symonds, Deborah Walton, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 24, 2004
Comparative preclinical pharmacokinetic and metabolic studies of the combretastatin prodrugs combretastatin A4 phosphate and A1 phosphateIan G Kirwan, Paul M Loadman, David J Swaine, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society|March 17, 2004
In vitro study of GDNF release from biodegradable PLGA microspheresAnne Aubert-Pouëssel, Marie-Claire Venier-Julienne, Anne Clavreul, et al.
Pilot and Feasibility Studies|September 3, 2022
A trial of intra-pleural bacterial immunotherapy in malignant pleural mesothelioma (TILT) - a randomised feasibility study using the trial within a cohort (TwiC) methodologyAnna C Bibby, Natalie Zahan-Evans, Emma Keenan, et al.
BMC Palliative Care|June 13, 2026
Understanding pain in malignant mesothelioma: a prospective, longitudinal cohort studyCatriona R Mayland, Michelle Collinson, Sam H Ahmedzai, et al.
Neoplasia (New York, N.Y.)|February 22, 2005
MMP-10 is overexpressed, proteolytically active, and a potential target for therapeutic intervention in human lung carcinomasJason H Gill, Ian G Kirwan, Jill M Seargent, et al.
Journal of Natural Products|October 29, 2005
Antineoplastic agents. 509: synthesis of fluorcombstatin phosphate and related 3-halostilbenes(1)George R Pettit, Mathew D Minardi, Heidi J Rosenberg, et al.
British Journal of Cancer|February 6, 2003
Antitumour 2-(4-aminophenyl)benzothiazoles generate DNA adducts in sensitive tumour cells in vitro and in vivoC-O Leong, M Gaskell, E A Martin, et al.
Pageof 21

Showing results (181-190 of 204) with videos related to

Sort By:
Pageof 21
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 11, 2005
Differentiation and definition of vascular-targeted therapiesDietmar W Siemann, Michael C Bibby, Graham G Dark, et al.
British Journal of Cancer|June 28, 2002
Heterogeneity of O6-alkylguanine DNA-alkyltransferase expression in human breast tumoursM J Clemons, M C Bibby, H El Teraifi, et al.
BMJ Open|November 10, 2022
Protocol for a prospective observational cohort study collecting data on demographics, symptoms and biomarkers in people with mesothelioma (ASSESS-meso)Ruairi J H Conway, Jenny Symonds, Deborah Walton, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 24, 2004
Comparative preclinical pharmacokinetic and metabolic studies of the combretastatin prodrugs combretastatin A4 phosphate and A1 phosphateIan G Kirwan, Paul M Loadman, David J Swaine, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society|March 17, 2004
In vitro study of GDNF release from biodegradable PLGA microspheresAnne Aubert-Pouëssel, Marie-Claire Venier-Julienne, Anne Clavreul, et al.
Pilot and Feasibility Studies|September 3, 2022
A trial of intra-pleural bacterial immunotherapy in malignant pleural mesothelioma (TILT) - a randomised feasibility study using the trial within a cohort (TwiC) methodologyAnna C Bibby, Natalie Zahan-Evans, Emma Keenan, et al.
BMC Palliative Care|June 13, 2026
Understanding pain in malignant mesothelioma: a prospective, longitudinal cohort studyCatriona R Mayland, Michelle Collinson, Sam H Ahmedzai, et al.
Neoplasia (New York, N.Y.)|February 22, 2005
MMP-10 is overexpressed, proteolytically active, and a potential target for therapeutic intervention in human lung carcinomasJason H Gill, Ian G Kirwan, Jill M Seargent, et al.
Journal of Natural Products|October 29, 2005
Antineoplastic agents. 509: synthesis of fluorcombstatin phosphate and related 3-halostilbenes(1)George R Pettit, Mathew D Minardi, Heidi J Rosenberg, et al.
British Journal of Cancer|February 6, 2003
Antitumour 2-(4-aminophenyl)benzothiazoles generate DNA adducts in sensitive tumour cells in vitro and in vivoC-O Leong, M Gaskell, E A Martin, et al.
Pageof 21